Cytokinetics (CYTK) Stock Forecast & Price Target

Compare

1,234 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CYTK Analyst Ratings

Strong Buy

14 Buy

2 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Cytokinetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CYTK Stock 12 Month Forecast

Average Price Target

$91.71

▲(36.93% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $91.71 with a high forecast of $136.00 and a low forecast of $61.00. The average price target represents a 36.93% change from the last price of $66.98.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","137":"$137","56.75":"$56.8","83.5":"$83.5","110.25":"$110.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":136,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$136.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":91.71428571428571,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$91.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$61.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,56.75,83.5,110.25,137],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.16,70.60923076923076,76.05846153846153,81.50769230769231,86.95692307692308,92.40615384615384,97.85538461538462,103.30461538461539,108.75384615384615,114.20307692307692,119.65230769230769,125.10153846153847,130.55076923076922,{"y":136,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.16,67.20263736263736,69.24527472527473,71.28791208791208,73.33054945054944,75.3731868131868,77.41582417582417,79.45846153846153,81.5010989010989,83.54373626373626,85.58637362637361,87.62901098901098,89.67164835164834,{"y":91.71428571428571,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.16,64.84,64.52,64.2,63.879999999999995,63.559999999999995,63.239999999999995,62.92,62.6,62.28,61.96,61.64,61.32,{"y":61,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":49.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.92,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.21,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.84,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.59,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$136.00

Average Price Target$91.71

Lowest Price Target$61.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emily Field

Barclays

$87

Buy

29.89%

Upside

Reiterated

02/19/26

Cytokinetics transferred with Overweight at BarclaysCytokinetics transferred with Overweight at Barclays

Joseph Pantginis

H.C. Wainwright

$136

Buy

103.05%

Upside

Reiterated

02/17/26

MYQORZO: EC Approval, Differentiated Label, and Global HCM Expansion Support Buy on CYTK

Tessa Romero

J.P. Morgan

Buy

―

Reiterated

02/08/26

Cytokinetics: Buy Rating on Myqorzo’s oHCM Opportunity and 2026 Commercial Inflection Catalysts

Srikripa Devarakonda

Truist Financial

$84→$92

Buy

37.35%

Upside

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK), Twist Bioscience (NASDAQ: TWST) and Centene (NYSE: CNC)

Jason Zemansky

Bank of America Securities

$65→$66

Hold

-1.46%

Downside

Reiterated

02/03/26

Bank of America Securities Remains a Hold on Cytokinetics (CYTK)

Maxwell Skor

Morgan Stanley

$90

Buy

34.37%

Upside

Reiterated

01/30/26

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Rhythm Pharmaceuticals (NASDAQ: RYTM)

Leonid Timashev

RBC Capital

$95

Buy

41.83%

Upside

Reiterated

01/21/26

RBC Capital Reaffirms Their Buy Rating on Cytokinetics (CYTK)

Mayank Mamtani

B. Riley Securities

$90→$108

Buy

61.24%

Upside

Reiterated

01/21/26

Cytokinetics price target raised to $108 from $90 at B. RileyCytokinetics price target raised to $108 from $90 at B. Riley

Yasmeen Rahimi

Piper Sandler

$107

Buy

59.75%

Upside

Reiterated

01/13/26

Piper Sandler Sticks to Their Buy Rating for Cytokinetics (CYTK)

Roanna Ruiz

Leerink Partners

Buy

―

Reiterated

01/13/26

Leerink Partners Keeps Their Buy Rating on Cytokinetics (CYTK)

Cory Kasimov

Evercore ISI

$80

Buy

19.44%

Upside

Reiterated

12/22/25

Cytokinetics (CYTK) Receives a Buy from Evercore ISI

Jason Butler

Citizens JMP

$78→$88

Buy

31.38%

Upside

Reiterated

12/22/25

Cytokinetics price target raised to $88 from $78 at CitizensCytokinetics price target raised to $88 from $78 at Citizens

Serge Belanger

Needham

$72→$84

Buy

25.41%

Upside

Reiterated

12/22/25

Cytokinetics (CYTK): Myqorzo’s Differentiated Profile, Global Upside, and Pipeline Catalysts Support Raised Target and Buy Rating

James Condulis

Stifel Nicolaus

$95

Buy

41.83%

Upside

Assigned

12/22/25

Analysts Offer Insights on Healthcare Companies: Altimmune (NASDAQ: ALT), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cytokinetics (NASDAQ: CYTK)

Paul Choi

Goldman Sachs

$95

Buy

41.83%

Upside

Upgraded

12/18/25

Cytokinetics upgraded to Buy from Neutral at Goldman SachsCytokinetics upgraded to Buy from Neutral at Goldman Sachs

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emily Field

Barclays

$87

Buy

29.89%

Upside

Reiterated

02/19/26

Cytokinetics transferred with Overweight at BarclaysCytokinetics transferred with Overweight at Barclays

Joseph Pantginis

H.C. Wainwright

$136

Buy

103.05%

Upside

Reiterated

02/17/26

MYQORZO: EC Approval, Differentiated Label, and Global HCM Expansion Support Buy on CYTK

Tessa Romero

J.P. Morgan

Buy

―

Reiterated

02/08/26

Cytokinetics: Buy Rating on Myqorzo’s oHCM Opportunity and 2026 Commercial Inflection Catalysts

Srikripa Devarakonda

Truist Financial

$84→$92

Buy

37.35%

Upside

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK), Twist Bioscience (NASDAQ: TWST) and Centene (NYSE: CNC)

Jason Zemansky

Bank of America Securities

$65→$66

Hold

-1.46%

Downside

Reiterated

02/03/26

Bank of America Securities Remains a Hold on Cytokinetics (CYTK)

Maxwell Skor

Morgan Stanley

$90

Buy

34.37%

Upside

Reiterated

01/30/26

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Rhythm Pharmaceuticals (NASDAQ: RYTM)

Leonid Timashev

RBC Capital

$95

Buy

41.83%

Upside

Reiterated

01/21/26

RBC Capital Reaffirms Their Buy Rating on Cytokinetics (CYTK)

Mayank Mamtani

B. Riley Securities

$90→$108

Buy

61.24%

Upside

Reiterated

01/21/26

Cytokinetics price target raised to $108 from $90 at B. RileyCytokinetics price target raised to $108 from $90 at B. Riley

Yasmeen Rahimi

Piper Sandler

$107

Buy

59.75%

Upside

Reiterated

01/13/26

Piper Sandler Sticks to Their Buy Rating for Cytokinetics (CYTK)

Roanna Ruiz

Leerink Partners

Buy

―

Reiterated

01/13/26

Leerink Partners Keeps Their Buy Rating on Cytokinetics (CYTK)

Cory Kasimov

Evercore ISI

$80

Buy

19.44%

Upside

Reiterated

12/22/25

Cytokinetics (CYTK) Receives a Buy from Evercore ISI

Jason Butler

Citizens JMP

$78→$88

Buy

31.38%

Upside

Reiterated

12/22/25

Cytokinetics price target raised to $88 from $78 at CitizensCytokinetics price target raised to $88 from $78 at Citizens

Serge Belanger

Needham

$72→$84

Buy

25.41%

Upside

Reiterated

12/22/25

Cytokinetics (CYTK): Myqorzo’s Differentiated Profile, Global Upside, and Pipeline Catalysts Support Raised Target and Buy Rating

James Condulis

Stifel Nicolaus

$95

Buy

41.83%

Upside

Assigned

12/22/25

Analysts Offer Insights on Healthcare Companies: Altimmune (NASDAQ: ALT), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cytokinetics (NASDAQ: CYTK)

Paul Choi

Goldman Sachs

$95

Buy

41.83%

Upside

Upgraded

12/18/25

Cytokinetics upgraded to Buy from Neutral at Goldman SachsCytokinetics upgraded to Buy from Neutral at Goldman Sachs

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cytokinetics

3 Months

xxx

Success Rate

13/21 ratings generated profit

Average Return

+26.76%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +26.76% per trade.

1 Year

Salim SyedMizuho Securities

Success Rate

36/51 ratings generated profit

Average Return

+33.82%

a rating ―

Copying Salim Syed's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +33.82% per trade.

2 Years

xxx

Success Rate

17/21 ratings generated profit

Average Return

+39.09%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.95% of your transactions generating a profit, with an average return of +39.09% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CYTK Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CYTK has received 33 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. CYTK average Analyst price target in the past 3 months is 91.71.

Each month's total comprises the sum of three months' worth of ratings.

CYTK Financial Forecast

CYTK Earnings Forecast

Next quarter’s earnings estimate for CYTK is -$1.56 with a range of -$2.14 to -$1.26. The previous quarter’s EPS was -$2.55. CYTK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year CYTK has Performed in-line its overall industry.

CYTK Sales Forecast

Next quarter’s sales forecast for CYTK is $6.93M with a range of $0.00 to $30.00M. The previous quarter’s sales results were $1.94M. CYTK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year CYTK has Performed in-line its overall industry.

CYTK Stock Forecast FAQ

What is CYTK’s average 12-month price target, according to analysts?

Based on analyst ratings, Cytokinetics’s 12-month average price target is 91.71.

What is CYTK’s upside potential, based on the analysts’ average price target?

Cytokinetics has 36.93% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CYTK a Buy, Sell or Hold?

Cytokinetics has a consensus rating of Strong Buy which is based on 14 buy ratings, 2 hold ratings and 0 sell ratings.

What is Cytokinetics’s price target?

The average price target for Cytokinetics is 91.71. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $136.00 ,the lowest forecast is $61.00. The average price target represents 36.93% Increase from the current price of $66.98.

What do analysts say about Cytokinetics?

Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of CYTK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Cytokinetics (CYTK) Stock Forecast & Price Target

CYTK Analyst Ratings

CYTK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cytokinetics

CYTK Analyst Recommendation Trends

CYTK Financial Forecast

CYTK Earnings Forecast

CYTK Sales Forecast

CYTK Stock Forecast FAQ

Detailed List of Analyst Forecasts